LONDON - Chroma Therapeutics Ltd. landed a deal boasting a headline value of $1 billion with GlaxoSmithKline (GSK) plc, in which Chroma will apply its chemical motif technology for targeting small molecules directly into macrophages, to develop treatments for autoimmune and other inflammatory diseases. (BioWorld International) Read More
